| | ||||||||||
| 1 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| NORETHINDRONE (is an active metabolite)
| NORETHINDRONE |
GENITO | ORAL | Cmax 87.8 NANOMOLAR Tmax 1.83 HOUR F 64 PERCENT VD 260 LITER (65 KILOGRAM) PPB 61 PERCENT Cl 26 LITER / HOUR (65 KILOGRAM) HT 8.51 HOUR | PROGESTERONE RECEPTOR PDB 2W8Y (RU486 BOUND TO THE PROGESTERONE RECEPTOR IN A DESTABILIZED AGONISTIC CONFORMATION) LIGAND CODE = NDR (link to the list of PDB complexes) Download experimental 3D coordinates of NDR with added hydrogens | PROGESTERONE RECEPTOR AGONIST CHEMBL208 PROGESTERONE RECEPTOR P06401 PROGESTERONE RECEPTOR HOMO SAPIENS TRANSCRIPTION FACTOR NUCLEAR RECEPTOR NR3 NR3C NR3C3 | ANSM (in French) | |||
| 2 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| NORETHINDRONE ACETATE (has an active metabolite)
| NORETHINDRONE ACETATE |
GENITO | ORAL TRANSDERMAL INTRAMUSCULAR | PROGESTERONE RECEPTOR | PROGESTERONE RECEPTOR AGONIST CHEMBL208 PROGESTERONE RECEPTOR P06401 PROGESTERONE RECEPTOR HOMO SAPIENS TRANSCRIPTION FACTOR NUCLEAR RECEPTOR NR3 NR3C NR3C3 | ANSM (in French) | ||||
